Diagnostic MicroRNA Signatures to Support Classification of Pulmonary Hypertension

被引:1
作者
Errington, Niamh [1 ]
Zhou, Li [2 ]
Rhodes, Christopher J. [1 ]
Fong, Yiu-Lian [3 ]
Zhou, Lihan [2 ]
Kariotis, Sokratis [4 ]
Harder, Eileen [5 ,6 ]
Waxman, Aaron [5 ,6 ]
Jatkoe, Timothy [3 ]
Wharton, John [1 ]
Thompson, A. A. Roger [7 ,8 ,9 ]
Condliffe, Robin A. [7 ,8 ,9 ]
Kiely, David G. [7 ,8 ,9 ]
Howard, Luke S. [1 ,10 ]
Toshner, Mark [11 ,12 ]
He, Cheng [2 ]
Wang, Dennis [1 ,4 ]
Wilkins, Martin R. [1 ]
Lawrie, Allan [1 ]
机构
[1] Imperial Coll London, Natl Heart & Lung Inst, Hammersmith Campus,Du Cane Rd, London W12 0NN, England
[2] MiRXES Lab, Singapore, Singapore
[3] Johnson & Johnson, Janssen Pharmaceut Co, Raritan, NJ USA
[4] ASTAR, Bioinformat Inst, Singapore, Singapore
[5] Brigham & Womens Hosp, Boston, MA USA
[6] Harvard Med Sch, Boston, MA USA
[7] Univ Sheffield, Div Clin Med, Sheffield, England
[8] Sheffield Teaching Hosp Fdn Trust, Sheffield Pulm Vasc Dis Unit, Sheffield, England
[9] NIHR BRC Sheffield, Sheffield, England
[10] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, London, England
[11] Papworth NHS Fdn, Cambridge, England
[12] Univ Cambridge, Dept Med, Cambridge, England
关键词
biomarkers; early diagnosis; machine learning; miRNA; pulmonary hypertension; ARTERIAL-HYPERTENSION; SURVIVAL;
D O I
10.1161/CIRCGEN.124.004862
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND:Patients with pulmonary hypertension (PH) are classified based on disease pathogenesis and hemodynamic drivers. Classification informs treatment. The heart failure biomarker NT-proBNP (N-terminal pro-B-type natriuretic peptide) is used to help inform risk but is not specific to PH or sub-classification groups. There are currently no other biomarkers in clinical use to help guide diagnosis or risk.METHODS:We profiled a retrospective cohort of 1150 patients from 3 expert centers with PH and 334 non-PH symptomatic controls (disease controls) from the United Kingdom to measure circulating levels of 650 microRNAs (miRNAs) in serum. NT-proBNP (ELISA) and 326 well-detected miRNAs (polymerase chain reaction) were prioritized by feature selection using multiple machine learning models. From the selected miRNAs, generalized linear models were used to describe miRNA signatures to differentiate PH and pulmonary arterial hypertension from the disease controls, and pulmonary arterial hypertension, PH due to left heart disease, PH due to lung disease, and chronic thromboembolic pulmonary hypertension from other forms of PH. These signatures were validated on a UK test cohort and independently validated in the prospective CIPHER study (A Prospective, Multicenter, Noninterventional Study for the Identification of Biomarker Signatures for the Early Detection of Pulmonary Hypertension) comprising 349 patients with PH and 93 disease controls.RESULTS:NT-proBNP achieved a balanced accuracy of 0.74 and 0.75 at identifying PH and pulmonary arterial hypertension from disease controls with a threshold of 254 and 362 pg/mL, respectively but was unable to sub-categorize PH subgroups. In the UK cohort, miRNA signatures performed similarly to NT-proBNP in distinguishing PH (area under the curve of 0.7 versus 0.78), and pulmonary arterial hypertension (area under the curve of 0.73 versus 0.79) from disease controls. MicroRNA signatures outperformed NT-proBNP in distinguishing PH classification groups. External testing in the CIPHER cohort demonstrated that miRNA signatures, in conjunction with NT-proBNP, age, and sex, performed better than either NT-proBNP or miRNAs alone in sub-classifying PH.CONCLUSIONS:We suggest a threshold for NT-proBNP to identify patients with a high probability of PH, and the subsequent use of circulating miRNA signatures to help differentiate PH subgroups.
引用
收藏
页数:11
相关论文
共 30 条
[11]   Systematic evaluation of multiple qPCR platforms, NanoString and miRNA-Seq for microRNA biomarker discovery in human biofluids [J].
Hong, Lewis Z. ;
Zhou, Lihan ;
Zou, Ruiyang ;
Khoo, Chin Meng ;
Chew, Adeline Lai San ;
Chin, Chih-Liang ;
Shih, Shian-Jiun .
SCIENTIFIC REPORTS, 2021, 11 (01)
[12]  
Humbert M., 2022, EUR HEART J, V43, P3618, DOI [DOI 10.1183/13993003.00879-2022, DOI 10.1093/eurheartj/ehac237]
[13]   Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives [J].
Humbert, Marc ;
Guignabert, Christophe ;
Bonnet, Sebastien ;
Dorfmuller, Peter ;
Klinger, James R. ;
Nicolls, Mark R. ;
Olschewski, Andrea J. ;
Pullamsetti, Soni S. ;
Schermuly, Ralph T. ;
Stenmark, Kurt R. ;
Rabinovitch, Marlene .
EUROPEAN RESPIRATORY JOURNAL, 2019, 53 (01)
[14]   Regional cardiac expression and concentration of natriuretic peptides in patients with severe chronic heart failure [J].
Hystad, ME ;
Geiran, OR ;
Attramadal, H ;
Spurkland, A ;
Vege, Å ;
Simonsen, S ;
Hall, C .
ACTA PHYSIOLOGICA SCANDINAVICA, 2001, 171 (04) :395-403
[15]   Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis [J].
Janda, Surinder ;
Shahidi, Neal ;
Gin, Kenneth ;
Swiston, John .
HEART, 2011, 97 (08) :612-622
[16]   Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry [J].
Khou, Victor ;
Anderson, James J. ;
Strange, Geoff ;
Corrigan, Carolyn ;
Collins, Nicholas ;
Celermajer, David S. ;
Dwyer, Nathan ;
Feenstra, John ;
Horrigan, Mark ;
Keating, Dominic ;
Kotlyar, Eugene ;
Lavender, Melanie ;
McWilliams, Tanya J. ;
Steele, Peter ;
Weintraub, Robert ;
Whitford, Helen ;
Whyte, Ken ;
Williams, Trevor J. ;
Wrobel, Jeremy P. ;
Keogh, Anne ;
Lau, Edmund M. .
RESPIROLOGY, 2020, 25 (08) :863-871
[17]   Screening strategies for pulmonary arterial hypertension [J].
Kiely, David G. ;
Lawrie, Allan ;
Humbert, Marc .
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2019, 21 (0K) :9-20
[18]   Two prospective, multicenter studies for the identification of biomarker signatures for early detection of pulmonary hypertension (PH): The CIPHER and CIPHER-MRI studies [J].
Lawrie, Allan ;
Chin, Kelly ;
Fong, Yiu-Lian ;
Gargano, Cynthia ;
Gitton, Xavier ;
He, Cheng ;
Kiely, David G. ;
Zhou, Li ;
Zhou, Lihan ;
Maron, Bradley A. ;
Quinn, Debbie ;
Rosenkranz, Stephan ;
Stamatiadis, Dimitri ;
Toshner, Mark ;
Wilkins, Martin R. ;
Howard, Luke ;
Preston, Ioana R. .
PULMONARY CIRCULATION, 2024, 14 (02)
[19]  
Lim C-Y., 2021, CARDIOVASC PREV PHAR, V3, P15, DOI [10.36011/cpp.2021.3.e2, DOI 10.36011/CPP.2021.3.E2]
[20]   Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial Hypertension Results from the Pulmonary Hypertension Registry of the United Kingdom and Ireland [J].
Ling, Yi ;
Johnson, Martin K. ;
Kiely, David G. ;
Condliffe, Robin ;
Elliot, Charlie A. ;
Simon, J. ;
Gibbs, R. ;
Howard, Luke S. ;
Pepke-Zaba, Joanna ;
Sheares, Karen K. K. ;
Corriss, Paul A. ;
Fisher, Andrew J. ;
Lordan, James L. ;
Gaine, Sean ;
Coghlan, J. Gerry ;
Wort, S. John ;
Gatzoulis, Michael A. ;
Peacock, Andrew J. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 186 (08) :790-796